Prise en charge du risque hémorragique associé aux agents antiplaquettaires

@article{Martin2017PriseEC,
  title={Prise en charge du risque h{\'e}morragique associ{\'e} aux agents antiplaquettaires},
  author={Anne-C{\'e}line Martin and S Houssany-Pissot and Diane Zlotnik and Genevi{\`e}ve Taylor and Anne Godier},
  journal={Revue de M{\'e}decine Interne},
  year={2017},
  volume={38},
  pages={467-473}
}
5 Citations

References

SHOWING 1-10 OF 55 REFERENCES
The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor
TLDR
This study investigated the effect of the vasopressin agonist, desmopressin, on ticagrelor‐induced bleeding time prolongation in patients with acute coronary syndromes.
Boosting the coagulation restores haemostasis in ticagrelor-treated mice
TLDR
In mice dosed to complete P2Y12 inhibition, boosting coagulation by administration of rhFVIIa or rhFII within 90s after bleeding initiation can partly reverse ticagrelor-enhanced bleeding.
Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy
TLDR
The results of this study indicate that tranexamic acid potentially corrects defects in arachidonic acid-induced and ADP-induced platelet aggregation imposed by dual antiplatelet therapy, and support the use of tranExamic acid to partially reverse platelets aggregation dysfunction due to antiplatelets therapy.
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
TLDR
In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death, and a similar association was evident between major bleeding and ischemic events, including myocardial infarction and stroke.
The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study
TLDR
The results do not support the use of platelet transfusion to reverse the effects of ticagrelor, and platelet supplementation restored platelet aggregation in aspirin-spiked but not in ticgrelor-sp spiked samples.
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor.
TLDR
Biological evaluation of platelet function was consistent with the clinical impression, suggesting that platelet transfusion and desmopressin administration in the presence of ticagrelor had very little, if any, hemostatic effect.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
TLDR
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties
TLDR
The pharmacological properties, the pharmacokinetic and pharmacodynamic differences, and the clinical efficacy of the currently available P2Y12 receptor inhibitors are described.
No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents
  • L. Zakko, T. Rustagi, M. Douglas, L. Laine
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2017
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium
TLDR
Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
...
...